NDANASALSPRAY, METERED
Approved
Jun 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
LAZANDA (fentanyl citrate) by Hikma is analgesia. Approved for cancer pain, breakthrough pain, chronic neuropathic pain. First approved in 2011.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAZANDA is a metered nasal spray formulation of fentanyl citrate, a potent synthetic opioid agonist approved in 2011 for breakthrough pain management in opioid-tolerant patients. It works through mu-opioid receptor activation to provide rapid analgesia. The nasal route enables faster onset compared to oral formulations, making it suited for acute pain episodes in cancer and chronic neuropathic pain populations.
Peak5.7 years to LOE
LAZANDA is in peak lifecycle stage under Hikma ownership with stable market presence, though team size and growth investments are difficult to assess given limited public spending data.
Mechanism of Action
analgesia.
Indications (3)
Worked on LAZANDA at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.